{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T13:11:28Z","timestamp":1774703488291,"version":"3.50.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s11886-024-02114-6","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T07:02:15Z","timestamp":1723532535000},"page":"1153-1162","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Recent Advances in Positron Emission Tomography Radiotracers to Image Cardiac Amyloidosis"],"prefix":"10.1007","volume":"26","author":[{"given":"Ardel J.","family":"Romero Pab\u00f3n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier F.","family":"Clerc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shilpa","family":"Vijayakumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah A. M.","family":"Cuddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharmila","family":"Dorbala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"key":"2114_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/13506129.2022.2147636","volume":"29","author":"JN Buxbaum","year":"2022","unstructured":"Buxbaum JN, Dispenzieri A, Eisenberg DS, et al. Amyloid nomenclature 2022: Update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. Amyloid. 2022;29:213\u20139.","journal-title":"Amyloid"},{"key":"2114_CR2","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","volume":"68","author":"RH Falk","year":"2016","unstructured":"Falk RH, Alexander KM, Liao R, Dorbala S. AL (light-chain) cardiac amyloidosis: A review of diagnosis and therapy. J Am Coll Cardiol. 2016;68:1323\u201341.","journal-title":"J Am Coll Cardiol"},{"key":"2114_CR3","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73:2872\u201391.","journal-title":"J Am Coll Cardiol"},{"key":"2114_CR4","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1056\/NEJMra023144","volume":"349","author":"G Merlini","year":"2003","unstructured":"Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349:583\u201396.","journal-title":"N Engl J Med"},{"key":"2114_CR5","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.jcmg.2019.07.015","volume":"13","author":"S Dorbala","year":"2020","unstructured":"Dorbala S, Cuddy S, Falk RH. How to image cardiac amyloidosis: A practical approach. JACC Cardiovasc Imaging. 2020;13:1368\u201383.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2114_CR6","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.104.489187","volume":"112","author":"RH Falk","year":"2005","unstructured":"Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;112:2047\u201360.","journal-title":"Circulation"},{"key":"2114_CR7","doi-asserted-by":"publisher","first-page":"9629","DOI":"10.1073\/pnas.1121005109","volume":"109","author":"CE Bulawa","year":"2012","unstructured":"Bulawa CE, Connelly S, DeVit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci. 2012;109:9629\u201334.","journal-title":"Proc Natl Acad Sci"},{"key":"2114_CR8","doi-asserted-by":"crossref","unstructured":"Sanguinetti C, Minniti M, Susini V, et al. The journey of human transthyretin: synthesis, structure stability, and catabolism. Biomedicines. 2022;10:1906.","DOI":"10.3390\/biomedicines10081906"},{"key":"2114_CR9","doi-asserted-by":"crossref","unstructured":"Dorbala S, Ando Y, Bokhari S, et al. ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol. 2019;26:2065\u2013123.","DOI":"10.1007\/s12350-019-01760-6"},{"key":"2114_CR10","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1007\/s12350-019-01760-6","volume":"26","author":"S Dorbala","year":"2019","unstructured":"Dorbala S, Ando Y, Bokhari S, et al. ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 2 of 2-diagnostic criteria and appropriate utilization. J Nucl Cardiol. 2020;27:659\u201373.","journal-title":"J Nucl Cardiol"},{"key":"2114_CR11","doi-asserted-by":"publisher","first-page":"20S","DOI":"10.2967\/jnumed.122.264866","volume":"64","author":"S Dorbala","year":"2023","unstructured":"Dorbala S, Kijewski MF. Molecular imaging of systemic and cardiac amyloidosis: Recent advances and focus on the future. J Nucl Med. 2023;64:20S-28S.","journal-title":"J Nucl Med"},{"key":"2114_CR12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/1097-0339(200103)24:3<181::AID-DC1037>3.0.CO;2-D","volume":"24","author":"CD Guy","year":"2001","unstructured":"Guy CD, Jones CK. Abdominal fat pad aspiration biopsy for tissue confirmation of systemic amyloidosis: Specificity, positive predictive value, and diagnostic pitfalls. Diagn Cytopathol. 2001;24:181\u20135.","journal-title":"Diagn Cytopathol"},{"key":"2114_CR13","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1016\/j.mayocp.2020.06.029","volume":"95","author":"S Dasari","year":"2020","unstructured":"Dasari S, Theis JD, Vrana JA, et al. Amyloid typing by mass spectrometry in clinical practice: A comprehensive review of 16,175 samples. Mayo Clin Proc. 2020;95:1852\u201364.","journal-title":"Mayo Clin Proc"},{"key":"2114_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.proghi.2012.03.001","volume":"47","author":"RP Linke","year":"2012","unstructured":"Linke RP. On typing amyloidosis using immunohistochemistry. Detailled illustrations, review and a note on mass spectrometry. Prog Histochem Cytochem. 2012;47:61\u2013132.","journal-title":"Prog Histochem Cytochem"},{"key":"2114_CR15","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1161\/01.CIR.0000152819.97857.9D","volume":"111","author":"AM Maceira","year":"2005","unstructured":"Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111:186\u201393.","journal-title":"Circulation"},{"key":"2114_CR16","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.jcmg.2012.04.006","volume":"5","author":"FP Mongeon","year":"2012","unstructured":"Mongeon FP, Jerosch-Herold M, Coelho-Filho OR, Blankstein R, Falk RH, Kwong RY. Quantification of extracellular matrix expansion by CMR in infiltrative heart disease. JACC Cardiovasc Imaging. 2012;5:897\u2013907.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2114_CR17","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133:2404\u201312.","journal-title":"Circulation"},{"key":"2114_CR18","doi-asserted-by":"publisher","first-page":"716","DOI":"10.2967\/jnumed.120.247312","volume":"62","author":"S Dorbala","year":"2021","unstructured":"Dorbala S, Park MA, Cuddy S, et al. Absolute quantitation of cardiac (99m)Tc-pyrophosphate using cadmium-zinc-telluride-based SPECT\/CT. J Nucl Med. 2021;62:716\u201322.","journal-title":"J Nucl Med"},{"key":"2114_CR19","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.jcmg.2023.07.007","volume":"16","author":"OF Clerc","year":"2023","unstructured":"Clerc OF, Cuddy SAM, Robertson M, et al. Cardiac amyloid quantification using (124)I-evuzamitide ((124)I-P5+14) versus (18)F-florbetapir: A pilot PET\/CT study. JACC Cardiovasc Imaging. 2023;16:1419\u201332.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2114_CR20","doi-asserted-by":"publisher","first-page":"e221082","DOI":"10.1148\/radiol.221082","volume":"306","author":"YM Khor","year":"2023","unstructured":"Khor YM, Cuddy SAM, Singh V, Falk RH, Di Carli MF, Dorbala S. (99m)Tc bone-avid tracer cardiac scintigraphy: Role in noninvasive diagnosis of transthyretin cardiac amyloidosis. Radiology. 2023;306:e221082.","journal-title":"Radiology"},{"key":"2114_CR21","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s12350-018-01552-4","volume":"26","author":"V Singh","year":"2019","unstructured":"Singh V, Falk R, Di Carli MF, Kijewski M, Rapezzi C, Dorbala S. State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis. J Nucl Cardiol. 2019;26:158\u201373.","journal-title":"J Nucl Cardiol"},{"key":"2114_CR22","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s12350-016-0522-3","volume":"23","author":"V Dilsizian","year":"2016","unstructured":"Dilsizian V, Bacharach SL, Beanlands RS, et al. ASNC imaging guidelines\/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures. J Nucl Cardiol. 2016;23:1187\u2013226.","journal-title":"J Nucl Cardiol"},{"key":"2114_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s12350-018-1365-x","volume":"27","author":"YJ Kim","year":"2020","unstructured":"Kim YJ, Ha S, Kim YI. Cardiac amyloidosis imaging with amyloid positron emission tomography: A systematic review and meta-analysis. J Nucl Cardiol. 2020;27:123\u201332.","journal-title":"J Nucl Cardiol"},{"key":"2114_CR24","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1186\/s12872-021-02292-z","volume":"21","author":"Z Wu","year":"2021","unstructured":"Wu Z, Yu C. Diagnostic performance of CMR, SPECT, and PET imaging for the detection of cardiac amyloidosis: A meta-analysis. BMC Cardiovasc Disord. 2021;21:482.","journal-title":"BMC Cardiovasc Disord"},{"key":"2114_CR25","doi-asserted-by":"crossref","unstructured":"Uzuegbunam BC, Librizzi D, Hooshyar Yousefi B. PET radiopharmaceuticals for Alzheimer\u2019s disease and Parkinson\u2019s disease diagnosis, the current and future landscape. Molecules. 2020;25:977.","DOI":"10.3390\/molecules25040977"},{"key":"2114_CR26","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.bbrc.2013.05.063","volume":"436","author":"EB Martin","year":"2013","unstructured":"Martin EB, Williams A, Heidel E, Macy S, Kennel SJ, Wall JS. Peptide p5 binds both heparinase-sensitive glycosaminoglycans and fibrils in patient-derived AL amyloid extracts. Biochem Biophys Res Commun. 2013;436:85\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"2114_CR27","doi-asserted-by":"publisher","first-page":"7657","DOI":"10.3390\/molecules20057657","volume":"20","author":"JS Wall","year":"2015","unstructured":"Wall JS, Martin EB, Richey T, et al. Preclinical validation of the heparin-reactive peptide p5+14 as a molecular imaging agent for visceral amyloidosis. Molecules. 2015;20:7657\u201382.","journal-title":"Molecules"},{"key":"2114_CR28","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1007\/s12350-019-01885-8","volume":"28","author":"M Abulizi","year":"2021","unstructured":"Abulizi M, Sifaoui I, Wuliya-Gariepy M, et al. (18)F-sodium fluoride PET\/MRI myocardial imaging in patients with suspected cardiac amyloidosis. J Nucl Cardiol. 2021;28:1586\u201395.","journal-title":"J Nucl Cardiol"},{"key":"2114_CR29","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s12350-020-02356-1","volume":"29","author":"JPM Andrews","year":"2022","unstructured":"Andrews JPM, Trivieri MG, Everett R, et al. 18F-fluoride PET\/MR in cardiac amyloid: A comparison study with aortic stenosis and age- and sex-matched controls. J Nucl Cardiol. 2022;29:741\u20139.","journal-title":"J Nucl Cardiol"},{"key":"2114_CR30","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1007\/s12350-017-0799-x","volume":"25","author":"R Morgenstern","year":"2018","unstructured":"Morgenstern R, Yeh R, Castano A, Maurer MS, Bokhari S. (18)Fluorine sodium fluoride positron emission tomography, a potential biomarker of transthyretin cardiac amyloidosis. J Nucl Cardiol. 2018;25:1559\u201367.","journal-title":"J Nucl Cardiol"},{"key":"2114_CR31","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1016\/j.jacc.2016.09.953","volume":"68","author":"MG Trivieri","year":"2016","unstructured":"Trivieri MG, Dweck MR, Abgral R, et al. (18)F-sodium fluoride PET\/MR for the assessment of cardiac amyloidosis. J Am Coll Cardiol. 2016;68:2712\u20134.","journal-title":"J Am Coll Cardiol"},{"key":"2114_CR32","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2967\/jnumed.111.102053","volume":"54","author":"G Antoni","year":"2013","unstructured":"Antoni G, Lubberink M, Estrada S, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med. 2013;54:213\u201320.","journal-title":"J Nucl Med"},{"key":"2114_CR33","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jcmg.2014.09.018","volume":"8","author":"SP Lee","year":"2015","unstructured":"Lee SP, Lee ES, Choi H, et al. (11)C-Pittsburgh B PET imaging in cardiac amyloidosis. JACC Cardiovasc Imaging. 2015;8:50\u20139.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2114_CR34","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s12350-016-0638-5","volume":"25","author":"B Pilebro","year":"2018","unstructured":"Pilebro B, Arvidsson S, Lindqvist P, et al. Positron emission tomography (PET) utilizing Pittsburgh compound B (PIB) for detection of amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR). J Nucl Cardiol. 2018;25:240\u20138.","journal-title":"J Nucl Cardiol"},{"key":"2114_CR35","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1080\/13506129.2020.1798223","volume":"27","author":"K Takasone","year":"2020","unstructured":"Takasone K, Katoh N, Takahashi Y, et al. Non-invasive detection and differentiation of cardiac amyloidosis using (99m)Tc-pyrophosphate scintigraphy and (11)C-Pittsburgh compound B PET imaging. Amyloid. 2020;27:266\u201374.","journal-title":"Amyloid"},{"key":"2114_CR36","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.jcmg.2020.02.023","volume":"13","author":"S Rosengren","year":"2020","unstructured":"Rosengren S, Skibsted Clemmensen T, Tolbod L, et al. Diagnostic accuracy of [(11)C]PIB positron emission tomography for detection of cardiac amyloidosis. JACC Cardiovasc Imaging. 2020;13:1337\u201347.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2114_CR37","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.2967\/jnumed.121.263033","volume":"63","author":"YJ Choi","year":"2022","unstructured":"Choi YJ, Koh Y, Lee HJ, et al. Independent prognostic utility of (11)C-Pittsburgh compound B PET in patients with light-chain cardiac amyloidosis. J Nucl Med. 2022;63:1064\u20139.","journal-title":"J Nucl Med"},{"key":"2114_CR38","doi-asserted-by":"crossref","unstructured":"Park MA, Padera RF, Belanger A, et al. 18F-florbetapir binds specifically to myocardial light chain and transthyretin amyloid deposits: autoradiography study. Circ Cardiovasc Imaging. 2015;8:e002954.","DOI":"10.1161\/CIRCIMAGING.114.002954"},{"key":"2114_CR39","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1007\/s00259-014-2787-6","volume":"41","author":"S Dorbala","year":"2014","unstructured":"Dorbala S, Vangala D, Semer J, et al. Imaging cardiac amyloidosis: A pilot study using (18)F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging. 2014;41:1652\u201362.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2114_CR40","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.2967\/jnumed.118.221770","volume":"60","author":"EC Ehman","year":"2019","unstructured":"Ehman EC, El-Sady MS, Kijewski MF, et al. Early detection of multiorgan light-chain amyloidosis by whole-body (18)F-florbetapir PET\/CT. J Nucl Med. 2019;60:1234\u20139.","journal-title":"J Nucl Med"},{"key":"2114_CR41","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ajh.20381","volume":"79","author":"MA Gertz","year":"2005","unstructured":"Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol. 2005;79:319\u201328.","journal-title":"Am J Hematol"},{"key":"2114_CR42","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13550-018-0425-1","volume":"8","author":"L Baratto","year":"2018","unstructured":"Baratto L, Park SY, Hatami N, et al. (18)F-florbetaben whole-body PET\/MRI for evaluation of systemic amyloid deposition. EJNMMI Res. 2018;8:66.","journal-title":"EJNMMI Res"},{"key":"2114_CR43","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1007\/s00259-017-3814-1","volume":"45","author":"N Ezawa","year":"2018","unstructured":"Ezawa N, Katoh N, Oguchi K, Yoshinaga T, Yazaki M, Sekijima Y. Visualization of multiple organ amyloid involvement in systemic amyloidosis using (11)C-PiB PET imaging. Eur J Nucl Med Mol Imaging. 2018;45:452\u201361.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2114_CR44","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1080\/13506129.2018.1467313","volume":"25","author":"J Mestre-Torres","year":"2018","unstructured":"Mestre-Torres J, Lorenzo-Bosquet C, Cuberas-Borros G, et al. Utility of the (18)F-florbetapir positron emission tomography in systemic amyloidosis. Amyloid. 2018;25:109\u201314.","journal-title":"Amyloid"},{"key":"2114_CR45","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s00259-018-3995-2","volume":"45","author":"T Wagner","year":"2018","unstructured":"Wagner T, Page J, Burniston M, et al. Extracardiac (18)F-florbetapir imaging in patients with systemic amyloidosis: More than hearts and minds. Eur J Nucl Med Mol Imaging. 2018;45:1129\u201338.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2114_CR46","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1007\/s00259-019-04627-7","volume":"47","author":"YM Khor","year":"2020","unstructured":"Khor YM, Cuddy S, Harms HJ, et al. Quantitative [(18)F]florbetapir PET\/CT may identify lung involvement in patients with systemic AL amyloidosis. Eur J Nucl Med Mol Imaging. 2020;47:1998\u20132009.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2114_CR47","doi-asserted-by":"publisher","first-page":"247","DOI":"10.5858\/arpa.2016-0102-RA","volume":"141","author":"A Khoor","year":"2017","unstructured":"Khoor A, Colby TV. Amyloidosis of the lung. Arch Pathol Lab Med. 2017;141:247\u201354.","journal-title":"Arch Pathol Lab Med"},{"key":"2114_CR48","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.jcmg.2020.02.025","volume":"13","author":"SAM Cuddy","year":"2020","unstructured":"Cuddy SAM, Bravo PE, Falk RH, et al. Improved quantification of cardiac amyloid burden in systemic light chain amyloidosis: Redefining early disease? JACC Cardiovasc Imaging. 2020;13:1325\u201336.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2114_CR49","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/ehjci\/jead350","volume":"25","author":"Y Datar","year":"2024","unstructured":"Datar Y, Clerc OF, Cuddy SAM, et al. Quantification of right ventricular amyloid burden with 18F-florbetapir positron emission tomography\/computed tomography and its association with right ventricular dysfunction and outcomes in light-chain amyloidosis. Eur Heart J Cardiovasc Imaging. 2024;25:687\u201397.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2114_CR50","doi-asserted-by":"crossref","unstructured":"Slivnick J, Zareba KM, Varghese J, et al. Prevalence and haemodynamic profiles of pulmonary hypertension in cardiac amyloidosis. Open Heart. 2022;9:e001808.","DOI":"10.1136\/openhrt-2021-001808"},{"key":"2114_CR51","doi-asserted-by":"crossref","unstructured":"Clerc OF, Datar Y, Cuddy SAM, et al. Prognostic value of left ventricular 18F-florbetapir uptake in systemic light-chain amyloidosis. JACC Cardiovasc Imaging. 2024;17:911\u201322.","DOI":"10.1016\/j.jcmg.2024.05.002"},{"key":"2114_CR52","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.2967\/jnumed.115.169870","volume":"57","author":"WP Law","year":"2016","unstructured":"Law WP, Wang WY, Moore PT, Mollee PN, Ng AC. Cardiac amyloid imaging with 18F-Florbetaben PET: A pilot study. J Nucl Med. 2016;57:1733\u20139.","journal-title":"J Nucl Med"},{"key":"2114_CR53","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s00259-019-04290-y","volume":"46","author":"M Kircher","year":"2019","unstructured":"Kircher M, Ihne S, Brumberg J, et al. Detection of cardiac amyloidosis with (18)F-Florbetaben-PET\/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy. Eur J Nucl Med Mol Imaging. 2019;46:1407\u201316.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2114_CR54","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s12149-019-01372-7","volume":"33","author":"S Dietemann","year":"2019","unstructured":"Dietemann S, Nkoulou R. Amyloid PET imaging in cardiac amyloidosis: A pilot study using (18)F-flutemetamol positron emission tomography. Ann Nucl Med. 2019;33:624\u20138.","journal-title":"Ann Nucl Med"},{"key":"2114_CR55","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s12350-020-02363-2","volume":"29","author":"M Papathanasiou","year":"2022","unstructured":"Papathanasiou M, Kessler L, Carpinteiro A, et al. (18)F-flutemetamol positron emission tomography in cardiac amyloidosis. J Nucl Cardiol. 2022;29:779\u201389.","journal-title":"J Nucl Cardiol"},{"key":"2114_CR56","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s11307-021-01681-2","volume":"24","author":"JS Wall","year":"2022","unstructured":"Wall JS, Martin EB, Endsley A, et al. First in human evaluation and dosimetry calculations for peptide (124)I-p5+14-a novel radiotracer for the detection of systemic amyloidosis using PET\/CT imaging. Mol Imaging Biol. 2022;24:479\u201388.","journal-title":"Mol Imaging Biol"},{"key":"2114_CR57","doi-asserted-by":"publisher","first-page":"1275372","DOI":"10.3389\/fimmu.2023.1275372","volume":"14","author":"JS Foster","year":"2023","unstructured":"Foster JS, Balachandran M, Hancock TJ, et al. Development and characterization of a prototypic pan-amyloid clearing agent - a novel murine peptide-immunoglobulin fusion. Front Immunol. 2023;14:1275372.","journal-title":"Front Immunol"},{"key":"2114_CR58","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/j.jcmg.2023.08.009","volume":"16","author":"JS Wall","year":"2023","unstructured":"Wall JS, Martin EB, Lands R, et al. Cardiac Amyloid Detection by PET\/CT Imaging of Iodine ((124)I) Evuzamitide ((124)I-p5+14): A Phase 1\/2 Study. JACC Cardiovasc Imaging. 2023;16:1433\u201348.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2114_CR59","doi-asserted-by":"publisher","first-page":"977","DOI":"10.3390\/molecules25040977","volume":"25","author":"BC Uzuegbunam","year":"2020","unstructured":"Uzuegbunam BC, Librizzi D, Yousefi BH. PET radiopharmaceuticals for Alzheimer\u2019s disease and Parkinson\u2019s disease diagnosis, the current and future landscape. Molecules. 2020;25:977.","journal-title":"Molecules"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-024-02114-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-024-02114-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-024-02114-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T11:15:13Z","timestamp":1730805313000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-024-02114-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":59,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["2114"],"URL":"https:\/\/doi.org\/10.1007\/s11886-024-02114-6","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,13]]},"assertion":[{"value":"2 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}